Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved save search
New solar projects approved for Dominion Energy Virginia customers
Published: 2024-04-01 (Crawled : 14:00) - prnewswire.com
ENB | News 0 d | $34.86 2.83% 0.2% 9.9M
|
Industrial Services
|
| O: 0.06%
H: 0.0%
C: -1.02%
D | $49.84 2.62% -1.02% 4.1M
|
Utilities
|
| O: -0.16%
H: 0.26%
C: 0.1%
energy approved solar
Daqo New Energy's Subsidiary Xinjiang Daqo Proposes 2023 Cash Dividend for Approval at Its Annual Shareholders' Meeting
Published: 2024-04-01 (Crawled : 12:00) - prnewswire.com
DQ | $22.11 -2.64% 0.0% 300K
|
Process Industries
|
| O: 4.69%
H: 0.42%
C: -1.89%
approval meeting
3M Settlement with Public Water Suppliers to Address PFAS in Drinking Water Receives Final Court Approval
Published: 2024-04-01 (Crawled : 11:00) - prnewswire.com
MMM | $92.27 0.86% -0.18% 3.6M
|
Producer Manufacturing
|
| O: -13.06%
H: 3.61%
C: 3.26%
water approval
Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder
Published: 2024-04-01 (Crawled : 10:00) - globenewswire.com
LQDA M | $13.31 -3.62% -3.76% 830K
|
Health Technology
|
| O: 2.99%
H: 0.06%
C: -3.74%
fda approval favorable update potential
FDA Approves Treatments for Anemia in Chronic Kidney Disease, Hepatitis
Published: 2024-03-29 (Crawled : 19:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
PRGO | News | $30.8 2.87% -1.14% 1.2M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
fda hepatitis kidney anemia
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
Published: 2024-03-28 (Crawled : 12:00) - globenewswire.com
AEZS | $1.97 0.73% 6K
|
Health Technology
|
| O: -2.88%
H: 6.93%
C: 5.94%
approval
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Adults
Published: 2024-03-28 (Crawled : 11:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
keytruda lung cancer cell risk plus
Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients
Published: 2024-03-28 (Crawled : 07:00) - prnewswire.com
TVTX | $5.73 -1.21% -1.22% 950K
|
Health Technology
|
| O: 0.91%
H: 3.1%
C: -0.39%
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
|
| O: 10.27%
H: 0.4%
C: -25.91%
vafseo fda disease kidney anemia approved treatment
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
Published: 2024-03-28 (Crawled : 01:00) - prnewswire.com
AKBA | $1.36 -2.16% -2.21% 2.9M
|
Health Technology
|
| O: 10.27%
H: 0.4%
C: -25.91%
vafseo fda disease kidney anemia approval treatment dialysis
FDA Approves New Treatments for Two Rare Diseases
Published: 2024-03-27 (Crawled : 13:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
PRGO | News | $30.8 2.87% -1.14% 1.2M
|
Health Technology
|
| O: 0.84%
H: 1.48%
C: 1.29%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: 0.0%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 1.48%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: 0.0%
fda rare
COPD Market Poised for ‘Paradigm Shift’ with Potential Approvals in 2024: Glo...
Published: 2024-03-27 (Crawled : 13:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: 0.0%
copd potential market
COPD Market Poised for ‘Paradigm Shift’ with Potential Approvals in 2024: GlobalData
Published: 2024-03-27 (Crawled : 12:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.06%
H: 0.0%
C: 0.0%
copd potential market
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
Published: 2024-03-27 (Crawled : 12:30) - globenewswire.com
ALLR | $1.42 -7.79% -8.45% 460K
|
n/a
|
| O: 0.32%
H: 2.87%
C: 2.87%
approval cancer therapeutics advanced
EBRD and Erste Approve Financing for the Pupin Windfarm in Serbia
Published: 2024-03-27 (Crawled : 11:00) - globenewswire.com
ENLT | $16.03 -2.61% -2.68% 16K
|
n/a
|
| O: 0.18%
H: 1.52%
C: 0.93%
ATHA Energy Announces 92 Energy Obtains Court Approval
Published: 2024-03-27 (Crawled : 11:00) - globenewswire.com
NXE | $7.615 -0.33% -0.07% 4.2M
|
Non-Energy Minerals
|
| O: 0.13%
H: 1.18%
C: 1.18%
energy approval
UP Fintech Holding Limited’s Hong Kong Subsidiary Receives SFC Approval on Type 9 License to Provide Asset Management Services
Published: 2024-03-27 (Crawled : 10:00) - globenewswire.com
TIGR | $3.14 -0.32% -0.32% 530K
|
Finance
|
| O: -0.29%
H: 2.21%
C: 0.88%
management services license approval
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
Published: 2024-03-26 (Crawled : 23:00) - biospace.com/
MRK | News | $125.78 0.44% 0.0% 8.4M
|
Health Technology
|
| O: 0.38%
H: 0.24%
C: -0.21%
fda group treatment hypertension
FDA Approves Potential 'Game Changer' for Pulmonary Arterial Hypertension
Published: 2024-03-26 (Crawled : 23:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
fda hypertension potential
Tenon(R) Medical Announces Positive Fusion Results in First Patients Reaching 12-Month Follow Up in an IRB Approved, Multi-Centered, Post-Market Study Utilizing the Catamaran(R) SI Joint Fusion System
Published: 2024-03-26 (Crawled : 19:00) - biospace.com/
TNON | $0.7331 -2.25% -2.31% 31K
|
|
| O: 2.54%
H: 1.98%
C: -5.45%
first positive system medical results study
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Published: 2024-03-26 (Crawled : 18:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 1.84%
H: 0.24%
C: -0.14%
adzynma japan takeda approval injection
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.